-
JNK-IN-7: Selective JNK Inhibitor for MAPK Pathway and Ap...
2025-12-22
JNK-IN-7 is a highly selective, covalent JNK kinase inhibitor with nanomolar potency, widely used in MAPK signaling and apoptosis research. It targets all JNK isoforms and modulates innate immune signaling, making it a critical tool for dissecting c-Jun N-terminal kinase pathways and inflammation. This article outlines its mechanism, benchmarks, and best practices for laboratory use.
-
BRD4770: G9a Histone Methyltransferase Inhibitor for Prec...
2025-12-21
BRD4770 is a potent, cell-permeable G9a histone methyltransferase inhibitor with validated activity in modulating H3K9 methylation and inducing senescence in cancer models. This epigenetic modulator offers researchers a robust tool for dissecting tumorigenesis and cellular senescence mechanisms, especially in breast and pancreatic cancer research. Developed and supplied by APExBIO, BRD4770 meets stringent quality and reproducibility standards.
-
XAV-939: Potent Tankyrase 1/2 Inhibitor for Wnt/β-Catenin...
2025-12-20
XAV-939 is a highly selective tankyrase 1 and 2 inhibitor, used to modulate the Wnt/β-catenin signaling pathway in cancer, fibrosis, and stem cell differentiation models. Its nanomolar potency and mechanism—stabilizing axin to induce β-catenin degradation—make it a standard tool for dissecting pathway function. This article details its mechanism, benchmarks, and workflow integration, addressing both strengths and limitations.
-
Redefining Apoptosis Modulation: Strategic Insights for T...
2025-12-19
This thought-leadership article presents a mechanistic and strategic roadmap for translational scientists seeking to harness ABT-263 (Navitoclax)—a potent, oral Bcl-2 family inhibitor—in the evolving landscape of apoptosis and senescence research. By synthesizing recent chromatin-focused discoveries, advanced apoptosis assays, and practical workflow guidance, the article delineates how ABT-263 enables nuanced interrogation of cell fate, resistance profiling, and next-generation cancer model systems. Unlike standard product pages, this piece forges new conceptual ground by integrating chromatin dynamics, mitochondrial priming, and the translational promise of precision BH3 mimetics.
-
IWP-L6: Sub-Nanomolar Porcupine Inhibitor for Wnt Pathway...
2025-12-18
IWP-L6 stands out as a sub-nanomolar Porcupine inhibitor, purpose-built for precision Wnt signaling pathway inhibition in both developmental and cancer biology research. This guide details real-world protocols, advanced use-cases, and troubleshooting strategies that elevate Wnt signaling research with data-driven rigor.
-
Flavopiridol: Selective Pan-CDK Inhibitor for Cancer Rese...
2025-12-17
Flavopiridol (L868275) is a potent, selective pan-cdk inhibitor that targets CDK1, CDK2, CDK4, and CDK6, exerting robust cell cycle arrest and downregulating cyclin D1/D3 in cancer models. Peer-reviewed benchmarks validate its nanomolar potency and efficacy in xenograft models, positioning it as a core tool for translational oncology and cellular stress research.
-
DOT1L Inhibitor EPZ-5676: Precision Tool for MLL-Rearrang...
2025-12-16
EPZ-5676 is a potent and selective DOT1L histone methyltransferase inhibitor with nanomolar activity, enabling precise H3K79 methylation inhibition in MLL-rearranged leukemia research. Its high selectivity and in vivo efficacy make it a gold-standard antiproliferative agent for epigenetic studies in acute leukemia cell lines.
-
MLN4924 HCl Salt (SKU A3629): Practical Solutions for Rep...
2025-12-15
This article equips biomedical researchers and lab technicians with scenario-driven guidance for leveraging MLN4924 HCl salt (SKU A3629) in cell viability, apoptosis, and protein ubiquitination assays. Using real-world examples, we address common pain points and demonstrate how this NEDD8-activating enzyme inhibitor from APExBIO offers reproducibility, selectivity, and workflow reliability for advanced cancer biology and antiviral research.
-
Pazopanib (GW-786034): Multi-Targeted RTK Inhibitor for A...
2025-12-14
Pazopanib (GW-786034) is a potent multi-targeted receptor tyrosine kinase inhibitor with proven efficacy in angiogenesis inhibition and tumor growth suppression. It offers selective blockade of VEGFR, PDGFR, and FGFR signaling, supporting advanced cancer research and therapeutic model development.
-
H-89: Selective PKA Inhibitor for cAMP Signaling Pathway ...
2025-12-13
H-89 is a potent, selective cAMP-dependent protein kinase (PKA) inhibitor widely used in signal transduction studies. Its nanomolar potency and specificity enable precise modulation of cAMP signaling for research in cell proliferation, apoptosis, cancer biology, and neurodegenerative disease models. APExBIO supplies H-89 (SKU BA3584) as a validated, research-grade compound supporting high-confidence biochemical and cellular assays.
-
H-89: Selective cAMP-Dependent Protein Kinase Inhibitor f...
2025-12-12
H-89 is a highly selective inhibitor of cAMP-dependent protein kinase (PKA), enabling precise modulation of cAMP signaling pathways. The compound is validated for use in cell proliferation and apoptosis assays, and is a benchmark tool in studies dissecting PKA-mediated processes. Its nanomolar potency, stability, and specificity make H-89 essential for robust signal transduction and disease model research.
-
PKM2 Inhibitor (Compound 3k): Selective Pyruvate Kinase M...
2025-12-11
PKM2 inhibitor (compound 3k) is a potent, selective inhibitor of pyruvate kinase M2, a key enzyme in cancer cell glycolysis. This agent demonstrates nanomolar antiproliferative activity against multiple tumor lines and offers targeted disruption of aerobic glycolysis with minimal off-target cytotoxicity. The product is validated in both in vitro and in vivo models as a promising cancer cell metabolism inhibitor.
-
Nutlin-3a and the MDM2-p53 Axis: Advanced Insights for Ca...
2025-12-10
Explore advanced scientific perspectives on Nutlin-3a, a potent MDM2 inhibitor, and its unique role in p53 pathway activation, cell cycle arrest, and apoptosis induction. This article delivers differentiated, in-depth analysis for cancer research, highlighting mechanistic innovation and translational potential.
-
PF-562271 HCl: ATP-Competitive FAK/Pyk2 Inhibitor for Can...
2025-12-09
PF-562271 HCl is a nanomolar ATP-competitive FAK/Pyk2 inhibitor with high selectivity, enabling precise modulation of focal adhesion kinase signaling in cancer research. As a reversible inhibitor, it is validated in tumor growth inhibition and tumor microenvironment studies, making it a critical tool for translational oncology.
-
Bay 11-7821: Precision IKK Inhibitor for NF-κB Pathway Re...
2025-12-08
Bay 11-7821 (BAY 11-7082) empowers researchers to dissect the NF-κB signaling pathway, drive apoptosis regulation studies, and unravel the complexities of inflammatory signaling in cancer and immunology. This guide details applied workflows, troubleshooting strategies, and comparative insights to maximize the compound’s impact in advanced bench research.
355 records 8/24 page Previous Next First page 上5页 678910 下5页 Last page